Movement Alert｜REMEGEN Intraday Rise 5.13% in Regular Trading, profit turnaround and AbbVie RC148 licensing deal supported shares

Market Focus10-30

On October 30, REMEGEN recorded an Intraday Rise of 5.13% in Regular Trading, trading at HK$66.5 with turnover of HK$97.298 million.

The clearest catalyst was the company’s newly disclosed third-quarter results, which showed a sharp earnings improvement, alongside the previously announced exclusive licensing agreement with AbbVie for RC148.

For the first three quarters, revenue reached RMB6.764 billion, up 293.28% year over year, while net profit attributable to shareholders was RMB5.273 billion, reversing from a loss a year earlier. In the third quarter alone, revenue was RMB910.5 million, up 46.41%, and attributable net profit was RMB610.9 million. Public market reports also linked the share strength to the RC148 licensing transaction with AbbVie, which added to investor focus on the company’s external partnering value and commercialization progress.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment